Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Summary

Several prior studies have shown that dose reduction of Tumor Necrosis Factor (TNF)-inhibitors like adalimumab is possible in substantial number of rheumatic disease patients without an increase in disease activity. Biologic therapy is expensive, and is associated with patient burden as dose dependant risk for serious infections . A dose reduction will decrease the risk of side effects and result in substantial cost savings. Currently, most clinicians use Disease Activity Score in 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) to monitor dose tapering strategies. Although this approach is cost-effective, it might be improved by information on the extent of drug levels, as several studies have shown that adalimumab drug levels are associated with clinical outcome. Therefore, a study comparing dose reduction strategy using drug concentration with dose reduction strategy using disease activity is timely

Eligibility

Inclusion Criteria:

* Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;
* Starting adalimumab as the first biological therapy
* Who has agreed to participate (written informed consent);
* Age 18 years or older.

Exclusion Criteria:

* Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;
* Life expectancy shorter than follow-up period of the study;
* Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.

Conditions2

Browse More Trials